Elbasvir; Grazoprevir Patent Expiration

Elbasvir; Grazoprevir is Used for treating patients infected with hepatitis C virus. It was first introduced by Merck Sharp And Dohme Llc A Sub Of Merck And Co Inc in its drug Zepatier on Jan 28, 2016.


Elbasvir; Grazoprevir Patents

Given below is the list of patents protecting Elbasvir; Grazoprevir, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Zepatier US8871759 Inhibitors of hepatitis C virus replication May 04, 2031 Msd Sub Merck
Zepatier US7973040 Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors Jul 24, 2029 Msd Sub Merck



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Elbasvir; Grazoprevir's patents.

Given below is the list recent legal activities going on the following patents of Elbasvir; Grazoprevir.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 14 Dec, 2022 US7973040
Payment of Maintenance Fee, 8th Year, Large Entity 09 Mar, 2022 US8871759
Patent Term Extension Certificate 10 Dec, 2021 US7973040
Notice of Final Determination -Eligible 09 Mar, 2021 US7973040
Payment of Maintenance Fee, 8th Year, Large Entity 14 Dec, 2018 US7973040
FDA Final Eligibility Letter 10 Oct, 2018 US7973040
Payment of Maintenance Fee, 4th Year, Large Entity 13 Mar, 2018 US8871759
transaction for FDA Determination of Regulatory Review Period 30 Jan, 2018 US7973040
transaction for FDA Determination of Regulatory Review Period 21 Nov, 2017 US7973040
Second letter to regulating agency to determine regulatory review period 05 Sep, 2017 US7973040


Elbasvir; Grazoprevir's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List